These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Development of an Acrylamide-Based Inhibitor of Protein S-Acylation

submitted on 08.02.2021, 18:16 and posted on 09.02.2021, 12:59 by Saara-Anne Azizi, Tong Lan, Clémence Delalande, Rahul Kathayat, Bryan Dickinson

Protein S-acylation is a dynamic lipid post-translational modification that can modulate the localization and activity of target proteins. In humans, the installation of the lipid onto target proteins is catalyzed by a family of 23 Asp-His-His-Cys domain-containing protein acyltransferases (DHHC-PATs). DHHCs are increasingly recognized as critical players in cellular signaling events and in human disease. However, progress elucidating the functions and mechanisms of DHHC “writers” has been hampered by a lack of chemical tools to perturb their activity in live cells. Herein, we report the synthesis and characterization of PATi, a pan- DHHC inhibitor more potent than 2-bromopalmitate (2BP), the most commonly used DHHC inhibitor in the field. Possessing an acrylamide warhead, PATi pairs its gain in potency with decreases in both toxicity and inhibition of the S-acylation eraser enzymes – two of the major weaknesses of 2BP. Our studies show that PATi engages with DHHC family proteins in cells, inhibits protein S-acylation, and disrupts DHHC-regulated cellular events. PATi represents an improved chemical tool for untangling the complexities of DHHC-mediated cell signaling by protein S-acylation.


Molecular imaging approaches to interrogate mammalian signaling by lysine acylation

National Institute of General Medical Sciences

Find out more...

Identifying the mechanisms and biological impact of ERK lipidation in metabolic signaling

National Institute of Diabetes and Digestive and Kidney Diseases

Find out more...

Chemical approaches to interrogate the role of DHHCs in dynamic proteome lipid signaling

Swiss National Science Foundation

Find out more...


Email Address of Submitting Author


University of Chicago


United States

ORCID For Submitting Author


Declaration of Conflict of Interest

R.S.K. and B.C.D. have a patent on the DPP technology used in this work.